Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia-Reference-Cited by-同舟云学术

Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia

Published:2014-07-24 Issue:4 Volume:124 Page:503-510
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Treon Steven P.¹²,Tripsas Christina K.¹,Meid Kirsten¹,Kanan Sandra¹,Sheehy Patricia¹,Chuma Stacey¹,Xu Lian¹,Cao Yang¹,Yang Guang¹,Liu Xia¹,Patterson Christopher J.¹,Warren Diane¹,Hunter Zachary R.¹,Turnbull Barry³,Ghobrial Irene M.¹²,Castillo Jorge J.¹²

Affiliation:

1. Bing Center for Waldenström’s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA;

2. Harvard Medical School, Boston, MA; and

3. BioBridges Inc., Newton, MA

Abstract

Key Points Carfilzomib, rituximab, and dexamethasone (CaRD) produce overall and CR/VGPR responses in 87% and 36% of frontline WM patients, respectively. CaRD activity was not impacted by MYD88 and CXCR4 mutations and represents a neuropathy-sparing option for treating WM patients.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/124/4/503/1381754/503.pdf

Reference31 articles.

1. Clinicopathological definition of Waldenström’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia.;Owen;Semin Oncol,2003

2. Bortezomib in Waldenström’s macroglobulinemia.;Dimopoulos;Haematologica,2005

3. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom’s macroglobulinemia: results of WMCTG Trial 03-248.;Treon;Clin Cancer Res,2007

4. Bortezomib is active in patients with untreated or relapsed Waldenström’s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.;Chen;J Clin Oncol,2007

5. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.;Treon;J Clin Oncol,2009

Cited by 159 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Management of Waldenstrom Macroglobulinemia;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia;Current Hematologic Malignancy Reports;2024-07-06

3. Optimizing BTK Inhibition in Waldenström Macroglobulinemia;Journal of the National Comprehensive Cancer Network;2024-05

4. How to manage waldenström’s macroglobulinemia in 2024;Cancer Treatment Reviews;2024-04

5. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia;Current Hematologic Malignancy Reports;2024-03-27